Bret A. Lashner, MD Professor of Medicine Center for Inflammatory Bowel Disease Department of Gastroenterology and Hepatology Cleveland Clinic Cleveland, OH Elliot B. Davidson, MD, FAAFP Program Director, Family Medicine Residency Cleveland Clinic Akron General Director, Center for Family Medicine Akron, OH
Reviewers NJAFP: Lauren Carruth, MD AANP: Alana R. Wichmann, APN AAPA: Eric Peterson, EdM, FACEHP, CHCP
FPs: 0.75 AAFP Prescribed Credit
NPs: 0.75 Contact Hour of continuing education (which includes 0.5 hours of pharmacology)
PAs: 0.75 AAPA Category 1 CME Credit Medium
Patients with inflammatory bowel disease (IBD) who present with moderate to severe disease, or who relapse after treatment for mild disease will often require treatment with additional forms of therapy. Primary care clinicians are on the front line for monitoring their patients for treatment response and adverse events. This activity, the second in a 3-part series, addresses escalation of therapy as well as collaboration between primary care clinicians and specialists to monitor patients with IBD.
Developed by the New Jersey Academy of Family Physicians (NJAFP), the American Association of Nurse Practitioners (AANP), and the American Academy of PAs (AAPA) in cooperation with MCM Education. Target Audience
This program was developed for family medicine and primary care physicians, PAs, and nurse practitioners.
Upon completion of this educational activity, the participant should be able to:
Review criteria for clinical situations in which the intensity of IBD therapy should be increased and strategies for making these changes.
Discuss strategies to address medication-related side effects and treatment risks associated with IBD therapies.
Describe conditions that indicate the need for consultation with/referral to gastroenterology and surgery.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and reviewers have disclosed relevant financial relationships with commercial companies, and all conflicts have been resolved according to each respective provider's policy.
Bret A. Lashner, MD, has no conflicts of interest to disclose.
Elliot B. Davidson, MD, FAAFP, has no conflicts of interest to disclose.
Lauren Carruth, MD, has no conflicts of interest to disclose.
Alana R. Wichmann, APN, has disclosed the following: Speaker’s Bureau: AbbVie, Inc.
Eric Peterson, EdM, FACEHP, CHCP, has no conflicts of interest to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
This Enduring Material series activity, Treatment Patterns in Family Medicine: The Role of the Primary Care Clinician in Patient-Centered Management of IBD, from 10/15/2016 - 10/14/2017, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Approved for .75 AAFP Prescribed credits.
This program is approved for 0.75 contact hour of continuing education (which includes 0.5 hours of pharmacology) by the American Association of Nurse Practitioners. Program ID 16082265.
The activity was planned in accordance with AANP Accreditation Standards and Policies.
This program has been reviewed and is approved for a maximum of 0.75 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of 09/30/2016. Participants may submit the self-assessment at any time during that period.
This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
Commercial Support Statements
This activity is supported by educational grants from Shire; AbbVie, Inc.; and Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America, LLC.
There are no fees for participating in or receiving credit for this online educational activity.
Review the intended audience, learning objectives, and author disclosures.
Study the educational content online. Be sure to review both written and audio/slide content. Note: For optimal viewing on mobile devices, please view horizontally.
After reviewing the activity, click the "Post-Test" tab to select the type of credit you would like to receive. Then, continue to the post-activity survey and post-test. You will also be asked to complete an activity evaluation.
To receive AANP CE Credit: At the end of this activity, you will receive the program’s access code to complete the post-test/evaluation for this activity and claim credit. In the AANP CE Center for this program, you will click Get Certificate and choose Participation Codes. Enter the code provided and the post-test/evaluation will be available to you.
To receive AAPA Credit, you will be redirected to the AAPA website.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of their affiliated institutions;, the publisher; the New Jersey Academy of Family Physicians (NJAFP); the American Association of Nurse Practitioners (AANP); and the American Academy of PAs (AAPA); Shire; AbbVie, Inc.; or Salix Pharmaceuticals. Any medications, diagnostic procedures, or treatments discussed by the activity presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.